Dai, Xing et al. published their patent in 2014 |CAS: 1256359-96-2

The Article related to tetracyclic heterocycle preparation antiviral treatment hepatitis c, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Related Products of 1256359-96-2

On August 14, 2014, Dai, Xing; Liu, Hong; Palani, Anandan; He, Shuwen; Brockunier, Linda L.; Nargund, Ravi; Marcantonio, Karen; Zorn, Nicolas; Xiao, Dong; Peng, Xuanjia; Li, Peng; Guo, Tao published a patent.Related Products of 1256359-96-2 The title of the patent was Preparation of tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C. And the patent contained the following:

The invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. Compounds of formula I wherein A is C3-6 cycloalkyl and aromatic ring system; ring B is benzofuran, pyridinofuran pyrazolopyridine, etc.; E is absent and CR5R9; F is (CH)0-2 and (CH2)0-2; Z is N and CRa; Z1, Z2 and Z3 are independently CH and H, wherein 1 or 2 of Z1 – Z2 are N; R2 is H, C1-6 alkyl, and C1-6 alkoxy; R3 is H and C1-6 alkyl; R4 is C1-6 alkyl and C1-6 alkoxy; R5 is H, C1-6 alkyl, OH, halo, etc.; R9 is H; R5R9 taken together to form C3-6 cycloalkyl; R6 is H, OH, C1-6 alkyl, C1-6 haloalkyl, etc.; R7 is H and C1-6 alkyl; R6R7 taken together to form oxo; R8 is H, halo and OH and derivatives; R10 is H and C1-6 alkyl; Ra is H, halo and CN; dashed bond is single and double bond; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their anti-HCV activity. From the assay, it was determined that compound II exhibited IC50 values in the range of 3.784 nM to 4.674 nM. The experimental process involved the reaction of 4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole(cas: 1256359-96-2).Related Products of 1256359-96-2

The Article related to tetracyclic heterocycle preparation antiviral treatment hepatitis c, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Related Products of 1256359-96-2

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles